SCHEMBL1813003

SCHEMBL1813003

Cc1cc(C(OS(C)(=O)=O)(c2ccccc2)C(F)(F)F)cc(C)c1NC(=O)c1cccc(NC(=O)c2cccnc2Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
RXFP1 Q9HBX9 4/20 0.42
CSF1R P07333 3/20 0.42
BRAF P15056 2/20 0.42
LCK P06239 1/20 0.42
BTK Q06187 1/20 0.42
KCNK3 O14649 3/20 0.42
KCNK9 Q9NPC2 2/20 0.42
PTGES O14684 1/20 0.41
KIT P10721 1/20 0.41
KDR P35968 1/20 0.41
MAPK14 Q16539 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
MAPK10 P53779 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1812611 0.89 KMT2A (0.50) MEN1KMT2ARXFP1CSF1RBRAF
SCHEMBL1829076 0.84 MEN1 (0.52) MEN1KMT2ARXFP1CSF1RBRAF
SCHEMBL1824465 0.82 KMT2A (0.55) MEN1KMT2ARXFP1CSF1RBRAF
SCHEMBL1819735 0.82 KMT2A (0.55) MEN1KMT2ARXFP1CSF1RBRAF
SCHEMBL1812890 0.81 MEN1 (0.48) MEN1KMT2ARXFP1CSF1RBRAF
SCHEMBL1810230 0.81 KMT2A (0.48) MEN1KMT2ARXFP1CSF1RBRAF
SCHEMBL2261615 0.80 BRAF (0.44) RXFP1CSF1RBRAFLCKBTK
SCHEMBL1819533 0.79 KCNK3 (0.54) MEN1KMT2ARXFP1KCNK3KCNK9
SCHEMBL13497757 0.78 KMT2A (0.54) MEN1KMT2ACSF1RBRAFKCNK3
SCHEMBL1824389 0.77 KMT2A (0.53) MEN1KMT2ACSF1RBRAFKCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201603-A1 Novel Acylaminobenzamide Derivatives BAYER CROPSCIENCE AG (DE) 2011-08-18 US disclosed
EP-2318358-A2 ACYLAMINOBENZAMIDE DERIVATIVES Bayer CropScience AG (DE) 2011-05-11 EP disclosed
WO-2010015355-A2 NOVEL ACYLAMINOBENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201603-A1 Novel Acylaminobenzamide Derivatives KCNB1, KCNA5, KCNA7 MEN1 3469/4885KMT2A 676/4885RXFP1 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.